Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20747581 | 0.95 | MAPT (0.33) | TSHRMAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL20747626 | 0.90 | MAPT (0.36) | MAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL20747606 | 0.89 | MAPT (0.35) | TSHRMAPTLMNAALDH1A1CA1 | |
| SCHEMBL20747612 | 0.87 | MAPT (0.33) | TSHRMAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL20747655 | 0.83 | LMNA (0.40) | LMNA | |
| SCHEMBL22951491 | 0.82 | MAPT (0.43) | MAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL20747675 | 0.79 | MAPT (0.37) | MAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL20747769 | 0.78 | TSHR (0.35) | TSHRLMNAALDH1A1 | |
| SCHEMBL20747660 | 0.77 | TSHR (0.37) | TSHRLMNAALDH1A1L3MBTL1 | |
| SCHEMBL20747623 | 0.77 | LMNA (0.45) | MAPTLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | ALIOS BIOPHARMA, INC. (US) | 2019-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10208045-B2 | Aza-pyridone compounds and uses thereof | PNPO, ITPA, PDXK | TSHR 2479/4885MAPT 3216/4885LMNA 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.